Immune modulation of AML-blasts in therapy-refractory AML-patient in vivo with clinically approved response modifiers improves clinical status, blood cell regeneration and gives rise to leukemia specific adaptive and innate immune reactive cells. (March 2018) - Schmid, C.; Atzler, M.; Rank, A.; Inngjerdingen, M.; Rabe, A.; Deen, D.; Wang, R.; Eiz-Vesper, B.; Schmetzer, H.